Last reviewed · How we verify
NCT00846872
Effect of Continuous Subcutaneous GHRP-3 Infusion at 2 Dose Levels on the Physiological Secretion of the GH-IGF-I System, Blood Pressure, Glucose, Inflammatory Markers and Endothelial Function in Subjects With Insulin Resistance
Phase 1/Phase 2 trial testing GHRP-3 low dose in Insulin Resistance. Withdrawn.
1 March 2012
Quick facts
| Lead sponsor | Tulane University Health Sciences Center |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Start date | 1 July 2008 |
| Primary completion | 1 March 2012 |
| Estimated completion | 1 March 2012 |
Drugs / interventions tested
- GHRP-3 low dose — full drug profile →
- GHRP-3 high dose — full drug profile →
- Saline
Conditions studied
- Insulin Resistance — all drugs for Insulin Resistance →
- Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
Sponsor
Tulane University Health Sciences Center
Who can join
Adults 45 to 85, any sex, with Insulin Resistance or Endothelial Dysfunction. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Determine the relative effects of 0.1µg/kg/h and 0.5µg/kg/h GHRP-3 as compared to placebo in inducing physiological secretion of the GH-IGF-I system after continuous sc delivery in healthy older men and women with insulin resistance
Time frame: 6 months
Sponsor's own description
The hypothesis is that GHRP-3 will exert beneficial effects on endothelial function and insulin resistance in older men and women via hormonal (GH, IGF-I, IGFBP-3,-1, insulin) and non-hormonal actions (anti-inflammatory).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00846872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Insulin Resistance
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06768827 — New Mechanisms of Obesity · NA · recruiting
Other Tulane University Health Sciences Center trials
Trials by the same sponsor.
- NCT01832480 — Trichomonas Vaginalis Repeat Infections Among HIV Negative Women · Phase 3 · completed
- NCT00323375 — Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00846872 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tulane University Health Sciences Center
- Last refreshed: 6 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00846872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing